A standing executive order directs the federal government to push drugmakers toward the lowest prices they charge in other wealthy nations, a policy the administration says could cut some U.S. drug costs by 30% to 80%. The order aims at both the manufacturers who set list prices and the pharmacy middlemen who sit between them and patients, but it sets targets rather than guaranteed savings. Whether retirees ever see lower prices at the pharmacy counter depends on manufacturer cooperation and on legal questions that remain unsettled.
What “most favored nation” pricing would mean
At the center of the order is a simple premise: that Americans should pay no more for a given medication than the lowest price it commands in comparable developed countries. Federal health officials have since set most-favored-nation pricing targets and pressed manufacturers to move toward them, framing the current gap as other nations underpaying while U.S. patients cover the difference.
The approach would tie a domestic benchmark to foreign prices for certain drugs, a mechanism the administration argues could sharply lower costs for medications that are far cheaper abroad. Health officials have established specific pricing targets under the model and asked drugmakers to demonstrate progress, signaling that the policy is meant to be enforced rather than aspirational.
For older Americans, the stakes are concrete. Retirees fill more prescriptions than any other age group, and the medications targeted by such a benchmark are often the high-cost specialty and brand drugs that drive the largest out-of-pocket bills under Medicare Part D.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
The 30% to 80% claim, and why economists urge caution
The order’s most attention-grabbing element is the promised size of the savings. The administration has said the policy could lower prices “almost immediately, by 30% to 80%,” and in public remarks the president has cited figures ranging even higher, into the range of 59% to 90%. Those numbers are the administration’s own projection, not a measured result.
Analysts have urged caution on several fronts. A similar most-favored-nation effort during the prior Trump term was blocked in court before it could take effect, and the Congressional Research Service has flagged unresolved legal questions around the current approach, including how far the executive branch can go without new legislation from Congress.
The earlier attempt is instructive. During the first Trump term, a most-favored-nation rule aimed at certain Medicare Part B drugs was finalized late in 2020, only to be halted by federal courts on procedural grounds before it ever set a price, and the rule was later withdrawn. That history is part of why analysts treat the current order’s headline savings as a projection to be tested rather than a schedule of cuts already on the way.
There is also the matter of scope. Even a steep cut to a benchmark price does not automatically translate into a smaller pharmacy bill for every patient, because what a Medicare enrollee actually pays depends on plan design, deductibles and the out-of-pocket cap already written into law. A lower list price helps most where a person’s cost-sharing is tied to that price.
A separate law is already cutting some prices
While the most-favored-nation order remains a directive fighting through negotiation and the courts, a different federal effort is already changing prices at the pharmacy. Under the 2022 Inflation Reduction Act, Medicare negotiated prices directly with manufacturers for the first time, and the initial round of lower prices for ten high-cost drugs took effect in January 2026, with reported reductions of roughly 38% to 79% against earlier list prices.
The distinction matters for retirees trying to gauge what is real. The negotiation program is written into law, survived early legal challenges, and is expanding to more drugs in the years ahead, whereas the most-favored-nation order rests on executive authority that a court has questioned before. For someone comparing plans, the negotiated prices are a change already in force, while the order’s promised 30% to 80% cuts remain a target. That does not make the order meaningless, but it does change how much weight a household should put on it when budgeting for next year’s medications.
What it targets: manufacturers and pharmacy middlemen
Beyond pressing manufacturers, the order takes aim at pharmacy benefit managers, the intermediaries that negotiate drug coverage for insurers and employers and that the administration blames for inflating consumer costs. The stated goal is to “cut out the middlemen” and let patients buy certain drugs closer to the manufacturer’s price.
To that end, the order directs officials to facilitate direct-to-consumer purchasing programs, arrangements in which drugmakers would sell some products to patients at the most-favored-nation price without the usual layers in between. How widely manufacturers embrace such channels, and for which drugs, will shape whether the policy reaches ordinary buyers or stays confined to a handful of medications.
For now the order is best read as a directive that seeks lower prices rather than a change already reflected at the counter. Retirees weighing their Part D options for the coming year would be prudent to plan around the drug prices and plan rules currently in force, and to treat any most-favored-nation savings as a possibility still working its way through negotiation and the courts.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
More Financial Reading
